Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
Randomized Phase 3 results presented at ESMO put sac-TMT’s survival benefit and Merck’s development plans in focus.
TL;DR
- A randomized Phase 3 study presented at ESMO reported that sacituzumab tirumotecan reduced the risk of death by about one-third versus chemotherapy in advanced endometrial cancer.
- The drug is being developed by Merck and Kelun-Biotech, and the reported findings are from a clinical trial rather than an approval decision.
- Merck is running multiple global Phase 3 studies, while the presentation’s results still require regulatory review and further follow-up.
Researchers presented results from a randomized Phase 3 study at the European Society for Medical Oncology meeting in Madrid on October 26. STAT reported that sacituzumab tirumotecan, also called sac-TMT, lowered the risk of death by roughly one-third compared with chemotherapy in patients with advanced endometrial cancer. [1]
The treatment is an antibody-drug conjugate developed by Merck with China’s Kelun-Biotech. BioSpace independently reported the same overall-survival finding and described a reduction in progression or death as well, but the clinical result should be understood within the trial’s enrolled population and comparison arm. [2]
The result matters to Merck’s oncology portfolio because the company is pursuing a broad Phase 3 program for sac-TMT outside China. STAT reported 18 global Phase 3 studies, including 10 in women’s cancers, as Merck seeks to build products ahead of expected Keytruda patent loss in 2028. [1]
The reported survival result is not itself a marketing authorization, and the public reports do not settle how regulators will assess the full dataset, longer-term safety or which patient groups may ultimately qualify. Additional follow-up and regulatory review remain necessary before any treatment-use conclusions can be drawn. [2]
Why it matters
The trial could influence the competitive position of antibody-drug conjugates in gynecologic oncology and Merck’s longer-term portfolio planning, while the evidence remains specific to a studied population.
Editor's note
Clinical findings are reported as presented at ESMO; no treatment guidance inferred. Regulatory status remains unchanged in this story.